Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.
about
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancerThe potency and clinical efficacy of aromatase inhibitors across the breast cancer continuumAromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.
P2860
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Pharmacokinetics and pharmacod ...... postmenopausal breast cancer.
@en
Pharmacokinetics and pharmacod ...... postmenopausal breast cancer.
@nl
type
label
Pharmacokinetics and pharmacod ...... postmenopausal breast cancer.
@en
Pharmacokinetics and pharmacod ...... postmenopausal breast cancer.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... postmenopausal breast cancer.
@en
Pharmacokinetics and pharmacod ...... postmenopausal breast cancer.
@nl
P2093
P356
P1476
Pharmacokinetics and pharmacod ...... postmenopausal breast cancer.
@en
P2093
B P Haynes
L J Griggs
R C Coombes
P2860
P2888
P304
P356
10.1007/BF00688859
P577
1991-01-01T00:00:00Z